Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 52
- Registration Number
- NCT04355156
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Ulrik Lassen
- Target Recruit Count
- 300
- Registration Number
- NCT04341181
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT04337970
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
- Conditions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2020-02-06
- Target Recruit Count
- 58
- Registration Number
- NCT04258956
- Locations
- 🇵🇱
Maria Sklodowska-Curie National Research Institue of Oncology, Warsaw, Poland
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Case Comprehensive Cancer Center
- Registration Number
- NCT04197219
Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04118855
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 684
- Registration Number
- NCT04033991
- Locations
- 🇬🇧
Pfizer UK, London, United Kingdom
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03990571
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 25
- Registration Number
- NCT03839498
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 23
- Registration Number
- NCT03826589
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.